Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease
Por:
Llaurado, M, Ruiz, A, Majem, B, Ertekin, T, Colas, E, Pedrola, N, Devis, L, Rigau, M, Sequeiros, T, Montes, M, Garcia, M, Cabrera, S, Gil-Moreno, A, Xercavins, J, Castellvi, J, Garcia, A, Cajal, SRY, Moreno, G, Alameda, F, Vazquez-Levin, M, Palacios, J, Prat, J, Doll, A, Matias-Guiu, X, Abal, M, Reventos, J
Publicada:
25 jul 2012
Resumen:
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype.
Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC.
We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometria I tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC. (C) 2011 Published by Elsevier Ireland Ltd.
Filiaciones:
Llaurado, M:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Ruiz, A:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Majem, B:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Ertekin, T:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Colas, E:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Pedrola, N:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Devis, L:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Rigau, M:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Sequeiros, T:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Montes, M:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Garcia, M:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Cabrera, S:
Hosp Valle De Hebron, Serv Ginecol, Barcelona, Spain
Gil-Moreno, A:
Hosp Valle De Hebron, Serv Ginecol, Barcelona, Spain
Xercavins, J:
Hosp Valle De Hebron, Serv Ginecol, Barcelona, Spain
Castellvi, J:
Hosp Valle De Hebron, Serv Patol, Barcelona, Spain
Garcia, A:
Hosp Valle De Hebron, Serv Patol, Barcelona, Spain
Cajal, SRY:
Hosp Valle De Hebron, Serv Patol, Barcelona, Spain
Moreno, G:
Fdn MD Anderson, Madrid, Spain
Alameda, F:
Hosp del Mar, Serv Patol, Barcelona, Spain
Vazquez-Levin, M:
Consejo Nacl Invest Cient & Tecn, Inst Invest Biol & Biomed, RA-1033 Buenos Aires, DF, Argentina
Palacios, J:
Hosp Virgen del Rocio, Serv Patol, Seville, Spain
Prat, J:
Hosp Santa Creu & Sant Pau, Serv Patol, Barcelona, Spain
Doll, A:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
Matias-Guiu, X:
Hosp Arnau Vilanova, Serv Patol, Lleida, Spain
Abal, M:
Complejo Hosp Santiago de Compostela, Santiago, Spain
Reventos, J:
Vall dHebron Res Inst, Biomed Res Unit, Barcelona 08035, Spain
Univ Hosp, Barcelona 08035, Spain
|